Characteristics of patients at the 12-year follow-up visit and their medication according to their 12-year adherence

12-year adherence
Good adherence#Poor adherencep-value
Age years mean±sd61±1258±140.065§
Female sex52 (63.4%)56 (56.6%)0.365ƒ
BMI kg·m−228.1 (24.3–31.3)28.4 (24.6–31.2)0.640##
Smokers+40 (48.8%)51 (51.5%)0.766ƒ
Smoking history pack-years18 (9–33)17 (6–29)0.407##
Smoking history ≥10pack-years and post-BD FEV1/FVC <0.712 (30%)21 (42%)0.276ƒ
Number of comorbidities1 (0–3)1 (0–2)0.487##
Daily SABA13 (15.9%)8 (8.1%)0.161ƒ
Daily LABA54 (65.9%)41 (41.4%)0.002ƒ
Daily LTRA18 (22%)8 (8.2%)0.011ƒ
Daily theophylline4 (4.9%)0 (0%)0.040ƒ
Daily tiotropium5 (6.1%)3 (3.0%)0.471ƒ
Daily add-on drug57 (69.5%)44 (44.4%)0.001ƒ
Average prescribed ICS daily dose over 12 years µg budesonide equivalents810 (611–1043)805 (610–967)0.496##
Average dispensed ICS daily dose over 12 years µg budesonide equivalents803 (616–1075)320 (146–472)<0.001##

Data are presented as n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index; BD: bronchodilator; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SABA: short-acting β2-agonist; LABA: long-acting β2-agonist; LTRA: leukotriene receptor antagonist; ICS: inhaled corticosteroid. #: ≥80% adherence, n=82; : <80% adherence, n=99; +: including ex-smokers; §: independent-samples t-test; ƒ: Fisher's exact test; ##: Mann–Whitney U-test.